Back to results
US 9,868,724 B2Granted
Compounds
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsHui Lei, Xin Ma, Feng Ren, Xichen Lin, Robert W. Marquis, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
Claims21
A compound of Formula I or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is:
- 5 to 6 membered monocyclic heteroaryl optionally substituted with i) C1-C5 alkyl optionally substituted with CF3 or CN, ii) CH2F;
- or iii) one to two substituents independently selected from the group consisting of halo, methyl, methoxy and CN;
- wherein said 5 to 6 membered monocyclic heteroaryl is selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furanyl, furazanyl, thienyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, and tetrazolyl, or N-oxides thereof;
- or
- phenyl substituted with one to two substituents independently selected from the group consisting of CN, halo and methyl;
- R2 is C1-C3 alkyl;
- R3 is halo,
- R4 is H;
- R5 is C1-C3 alkyl,
- R6 is H or methyl;
- and
- R7 is tetrahydrofuranyl or tetrahydropyranyl, wherein said tetrahydrofuranyl or tetrahydropyranyl is optionally substituted with methyl.
11 more elements
Dependencies are inferred from the claim text.